COMPANY:

Sysmex Corp

"Today, OGT (Oxford Gene Technology) announced the launch of its newly updated NGS SureSeqTM CLL + CNV V3 Panel, which further incorporates their highly sensitive proprietary bait designs to offer more expansive coverage of disease-associated genes and enhanced CNV detection. This new panel now offers users more comprehensive variant detection to improve confidence in classification of CLL research samples to strengthen the understanding of CLL progression. ."

"Sysmex Inostics...is proud to announce its participation at the AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation, taking place on November 13-16, 2024 (San Diego, CA). Sysmex Inostics will be presenting two groundbreaking posters emphasizing clinical utility of HPV-SEQ, our commercially available next-generation sequencing (NGS) assay performed in a CLIA validated lab. The HPV-SEQ assay detects cell-free HPV DNA, enabling monitoring of treatment response and surveillance in HPV-related oropharyngeal cancer."

Sysmex Inostics Inc...announced that its RAS-RAF-SEQ Laboratory Developed Test has been granted the New York State Department of Health Clinical Laboratory Evaluation Program approval for clinical trial use. RAS-RAF-SEQ is a clinical grade, CLIA-validated liquid biopsy assay for the identification of the five most relevant targets for cancers impacted by the RAS-RAF and PI3K signaling pathways such as colorectal, pancreatic, gallbladder, ovarian, and lung cancers."

"Sysmex Inostics Inc...in collaboration with the University of Chicago Medicine announces the publication of results from the OPTIMAII trial in JAMA Oncology. Circulating tumor HPV-DNA (ctHPV-DNA) clearance, monitored using HPV-SEQ assay, predicts improved survival in patients with HPV-associated oropharyngeal cancer following nivolumab-based neoadjuvant therapy."

"Sysmex Corporation...announces...that it has expanded its strategic Alliance Agreement with QIAGEN N.V...to deepen their collaboration in genetic testing, including research and development, production, clinical development, and sales-marketing."

"OGT...announces the launch of the RNA-based SureSeq™ Myeloid Fusion Panel, a new next-generation sequencing (NGS) tool for identifying key fusion genes implicated in acute myeloid leukaemia (AML)."

"OGT...announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. Equipped with cutting-edge technology, the facilities will drive development of OGT’s trusted SureSeq™ next generation sequencing (NGS) product portfolio, as well as deliver expert-led training and enhanced opportunities for collaboration."

"OGT, A Sysmex Group Company, will showcase its soon to be launched SureSeq™ Myeloid MRD Panel at booth #1423 at the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, 14-18th November in Salt Lake City. The Next-generation sequencing (NGS) panel represents a substantial improvement on conventional flow cytometry and qPCR methods of detecting measurable residual disease (MRD) in acute myeloid leukaemia (AML) samples—providing outstanding sensitivity and coverage uniformity in one rapid and cost-effective assay."

"OGT, A Sysmex Group Company...and Intelliseq...are delighted to announce the release of GeneSpect™ Somatic Reporter for use with OGT’s SureSeq™ portfolio of next generation sequencing (NGS) panels. This advanced analytical reporting solution pairs state-of-the-art variant interpretation and reporting with OGT’s class-leading NGS panels and bioinformatics solutions. Users of SureSeq Myeloid panels can now benefit from insightful tertiary reporting for all myeloid malignancy content and variants with the GeneSpect Somatic Reporter."

"OGT, a Sysmex Group Company...is delighted to announce its new partnership with Intelliseq...This collaboration combines OGT's expansive SureSeq™ NGS portfolio with Intelliseq's state-of-the-art iFlow™ engine, resulting in a thorough and comprehensive NGS workflow—from sample to report. This advancement will greatly enhance lab productivity by automating the interpretation of NGS data and deliver actionable insights into cancer."

"Sysmex Corporation...is now covered by health insurance in Japan as a companion diagnostic for futibatinib,1 a treatment for unresectable biliary tract cancer2 harboring FGFR2 gene fusions3 that has progressed after chemotherapy. Futibatinib was developed by Taiho Pharmaceutical Co., Ltd....Riken Genesis Co., Ltd (HQ: Shinagawa-ku, Tokyo, Japan; President: Kenji Iwakabe), a subsidiary of Sysmex, will begin assay services in Japan corresponding to this insurance coverage from September 2023."

"OGT, a Sysmex Group Company...announces a new commercial partnership with Applied Spectral Imaging (ASI)...The agreement will grant OGT rights to market ASI’s proprietary cytogenetic imaging and analysis solutions in Great Britain, establishing a strategic partnership that combines the strengths of OGT’s CytoCell® FISH portfolio with ASI’s imaging and analysis capabilities to deliver operational efficiency in end user’s laboratories."